BMJ Open Diagnostic rates and treatment of dementia before and after launch of a national dementia policy: an observational study using English national databases

Naaheed Mukadam,¹ Gill Livingston,¹ Khadija Rantell,² Sam Rickman¹

To cite: Mukadam N, Livingston G, Rantell K, *et al.* Diagnostic rates and treatment of dementia before and after launch of a national dementia policy: an observational study using English national databases. *BMJ Open* 2014;**4**:e004119. doi:10.1136/bmjopen-2013-004119

► Prepublication history and additional material for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2013-004119>).

Received 26 September 2013
Revised 29 November 2013
Accepted 5 December 2013

CrossMark

¹Mental Health Sciences Unit, UCL, Charles Bell House, London, UK

²Biostatistics Group, Joint Research Office, UCL, London, UK

Correspondence to

Dr Naaheed Mukadam;
n.mukadam@ucl.ac.uk

ABSTRACT

Objectives: To assess the 2009 National Dementia Strategy's (NDS) impact on dementia diagnosis and treatment.

Setting and participants: Primary care data for England before and after launch of the NDS.

Primary outcome measures: We used nationally available data to estimate the trends over time in rates of dementia diagnoses recorded on the Quality Outcomes Framework (QOF) in Primary Care Trusts (PCT) and antidementia medication prescriptions from 2006/2007 (the first available figures) and the associated increase in cost relative to all other prescriptions. To establish PCT general practitioner (GP) QOF dementia recording validity, we correlated it with medication prescription using the NIC (net ingredient cost).

Results: Regression analysis showed that dementia diagnosis rate was lower prior to launch of the NDS and increased significantly after it was launched. The number of antidementia prescriptions and the cost of antidementia drugs relative to total PCT prescribing costs increased significantly after 2009. GP recording of dementia diagnosis correlated highly with prescription of cholinesterase inhibitors and memantine in the same area ($p < 0.001$ each year).

Conclusions: The launch of the NDS was associated with a significant increase in dementia diagnosis rates and prescriptions of antidementia drugs. We cannot establish the causality but this was a change from the prelaunch pattern. Further assessment of any intervention to increase the diagnoses should include an assessment of harm as well as potential benefit.

INTRODUCTION

The number of people with dementia is rising rapidly worldwide with increased life expectancy^{1 2} although the current cohort of older people may have slightly lower rates of dementia than their counterparts 20 years ago.³ Timely diagnosis of dementia can

Strengths and limitations of this study

- To our knowledge, this is the first study to examine the effect of healthcare policy on measurable health outcomes.
- Owing to the nature of the intervention being studied, we could not establish causality.
- The mechanisms of change in diagnostic and prescription rates following the policy launch remain unclear.

provide advice, treatment and support which empowers the person with dementia and their family, reduces crises and delays institutionalisation.⁴ It also leads to access to treatments, opportunities to take part in research, admission to specialist units when physically ill with a better experience of inpatient care⁵ and the ability to plan ahead.^{2 4 6} Nonetheless, diagnosis is often late in the illness and the majority of people with dementia are never given a diagnosis,⁷ even if they present to their general practitioner (GP) with symptoms.⁸ Consequently, early diagnosis is a key aim of current dementia policies in the Western world, including England's National Dementia Strategy⁹ but there is dispute about what strategies to use to increase the diagnosis rates, partly centring on the lack of definitive evidence to date on the efficacy of interventions to increase diagnosis⁶ or the usefulness of screening.¹⁰

Barriers to help-seeking for dementia include believing that the symptoms are due to normal ageing, lack of insight of the person with dementia,¹¹ low levels of knowledge about dementia¹² and a lack of confidence among GPs in discussing this diagnosis.^{7 13 14} The National Dementia Strategy (NDS) is the first UK government

initiative to focus on improving dementia care through: raising awareness about the illness; encouraging earlier diagnosis and intervention (primarily by increased access to specialist diagnostic services) and increasing the quality of care that people with dementia receive.⁹ It was launched in February 2009 and £150 million of funding was allocated to Primary Care Trusts (PCTs; who at that time commissioned health services for their local areas) to help achieve these objectives. The additional funding was primarily intended to improve diagnosis rates and the quality of dementia care, partly through provision of extra memory clinics. National dementia awareness campaigns were also launched but no specific funding was provided for these.¹⁵

The NDS is for England, but similar strategies were published for Scotland in June 2010 and Wales in February 2011. Dementia awareness campaigns have been launched in many countries to improve awareness of dementia and reduce stigma, in order to improve detection rates,^{7 16} but none of these have been evaluated in terms of their impact on measureable outcomes for people with dementia and their family carers.

Increasing diagnostic rates is theoretically possible through targeting known barriers. Our recent systematic review of interventions to increase either the number of people with diagnoses or timely diagnosis found that increasing the number of memory services was correlated with higher rates of dementia diagnosis¹⁷ and that they diagnosed people earlier in their illness than traditional old-age psychiatry services.¹⁸ In this paper we aim to explore whether there was an increase in diagnosis rates after the NDS compared with the preceding period and whether there was a corresponding increase in the rate of prescription of antedementia medications (cholinesterase inhibitors and memantine).

Objectives

- ▶ To assess whether the implementation of the NDS was associated with an increase in the rate of identification of people with dementia.
- ▶ To assess whether the NDS was associated with an increase in the treatment of dementia with antedementia medications.
- ▶ In addition, we aimed to consider the validity of dementia diagnoses on primary care registers.

METHODS

Data description

We established the following figures in England from national databases and the Alzheimer's Society Mapping the Dementia Gap publications:

- ▶ Annual national community-level prescribing data from 2003 to 2012 (calendar year).¹⁹
- ▶ National hospital-level prescribing data from 2007 to 2011 (calendar year).²⁰
- ▶ Yearly prescribing data of antedementia medications at Primary Care Trust (PCT; an administrative body

covering local primary care practices) level for 2008/2009 to 2011/2012 (fiscal year—April to March).²¹

- ▶ Number of people diagnosed with dementia on general practitioner (GP) databases by PCT from 2006/2007 to 2011/2012 (these are recorded by GP practice as quality and outcomes framework (QOF) data, fiscal year).²²
- ▶ Estimated true number of people with dementia in each PCT from 2010 to 2012.^{23 24}

We divided the number of GP-recorded dementia diagnoses (from QOF registers) by the estimated total number of people with dementia. We used the estimates in the Alzheimer's Society reports of the actual prevalence of dementia in each PCT for 2010–2012. We calculated the prevalence of dementia for preceding years using the same method used by the Alzheimer's Society in their reports.^{23 24}

As QOF data rely on GPs to enter dementia diagnosis onto their database, we wished to establish its validity, by comparison with an independent method of estimating the rate of dementia diagnosis, that is, with prescription levels for antedementia drugs calculated by:

- ▶ Net ingredient cost (NIC): the cost of the drug before discounts which does not include any dispensing costs or fees.
- ▶ Items dispensed: a prescription item refers to a single drug on a prescription so if a prescription form includes three medicines it is counted as three prescription items.²⁵ The potential disadvantage of relying on this method of calculating costs is that regional or temporal differences in prescribing policy may exist, for example, prescribing for a maximum of 1 month versus prescribing for a maximum of 3 months at a time, which could affect the results significantly.

We used community NIC as hospital NIC data was only available from 2007, was a relatively small figure (approximately 10% of total) and changed over time at around the same rate. We adjusted the NIC for inflation as specified by the Bank of England inflation calculator²⁶ to enable us to consider whether there were true differences between years. We correlated the NIC and the number of items dispensed to check whether they were similar. The correlation in 2008/2009 between the two was 0.974, in 2009/2010 was 0.968, in 2010/2011 was 0.965 and in 2011/2012 was 0.963 (all *p* values<0.001), so we concluded that they were very similar. We therefore report only NIC (as it would theoretically be less prone to variation over time and between districts) until 2012 when cholinesterase inhibitors came off-license as follows: Donepezil, February 2012; Galantamine, January 2012; Rivastigmine, July 2012.²⁷

We removed Hertfordshire from the dataset in all PCT level data for prescriptions and diagnoses due to West Hertfordshire PCT and East and North Hertfordshire PCT merging into NHS Hertfordshire after 2009/2010.

PCT-level prescribing data rows 'PCT unidentified doctors' and 'PCT unidentified deputising services' were

included when calculating totals but removed for comparison purposes with QOF data at PCT level. These data were never more than 0.06% of the total.

Statistical analysis

Numerical data were summarised using mean and SD or median and range depending on data distribution. We used Spearman's rank correlation to assess the monotonic association between two numerical variables.

Dementia diagnosis rates

We used negative binomial regression (NBR) models to assess the trend in diagnosis rates before and after the NDS, adjusting for cluster at PCT level. The NBR model is appropriate for count data and is similar to the Poisson regression model but is more appropriate in the presence of over-dispersion.²⁸ The NBR yield estimates of incidence rate ratio (IRR) and 95% CIs, where an IRR value of 1 indicates no impact on diagnosis rates. We used total population at risk as the offset variable in order to adjust for variable population denominators.

Dementia drug prescriptions

We used NBR to assess the trend in the number of dementia drug prescriptions, before and after the NDS, adjusting for cluster at PCT level with the total number of prescriptions as the offset variable.

We used multilevel linear regression to examine the effect of NDS on the relative prescription cost, adjusting for cluster at PCT level.²⁹ We used residual plots to investigate the assumptions of normality of residuals required by the multilevel models.

Validity of QOF figures

In order to explore whether areas with a calculated low diagnosis rate were explained by lack of recording of dementia diagnoses on the QOF registers, we assessed the relationship between dementia diagnosis rate and NIC costs per person diagnosed with dementia. If there was a bias in reporting then the mean NIC costs per person diagnosed with dementia would be higher than in other areas. We categorised diagnosis data and prescription data into quartiles and then assessed the Spearman's correlation between them.

All models are fitted with year as a fixed effect. Descriptive analyses were carried out in SPSS V.20. All models were fitted in Stata V.12.

RESULTS

Dementia diagnosis numbers and percentages

The number of people with a dementia diagnosis in England appeared to be similar from 2006 to 2008 but increased every year after 2008. This is shown in figure 1. Dementia diagnosis percentages are available online as a data supplement.

Figure 1 English National diagnosis numbers, 2006/2007 to 2011/2012. *y Axis begins at 200 000 as this was the baseline for numbers on the quality outcomes framework.

Dementia diagnosis rates

Table 1 shows the median number of recorded dementia diagnoses per PCT, the mean proportion of dementia diagnosed per PCT and change in the mean number diagnosed per PCT compared with the previous year, from 2006 to 2012.

Regression analysis showed that dementia diagnosis rates were lower in 2006–2008 compared with 2009, as shown in table 2. The dementia diagnosis rate increased by an estimated 4% in 2010 (IRR 1.04, 95% CI 1.03 to 1.05) and 12% in 2011 (IRR 1.12, 95% CI 1.11 to 1.13) compared with 2009.

Validity of QOF dementia diagnosis data

Dementia diagnosis rates were highly correlated with the prescribing data (see table 3). We divided PCTs into quartiles based on their dementia diagnosis rates and correlated these with the NIC (see table 4). PCTs in the quartile with the lowest diagnosis rates had lower correlations with the NIC than those with the higher diagnosis rates but this was not explained by higher prescribing costs per person diagnosed.

Antidementia drug prescriptions

The rate of prescriptions of antidementia drugs has increased dramatically since 2010 (see figure 2). There was a down-tick in 2012 in cost (see figure 3) although not in the number of prescriptions.

Regression analysis showed that the number of antidementia drug prescriptions increased significantly after 2009. The cost of antidementia drugs relative to total PCT prescriptions costs also increased significantly after 2009. All of these results are shown in table 2.

DISCUSSION

Overall, these results indicate that launch of the NDS is temporally linked to an increase in the diagnosis rates and in prescriptions of antidementia medications in England. We found that the mean number of dementia diagnoses per PCT per year (as reflected in GP recording of the diagnosis on their QOF register) and dementia diagnosis rate increased from the year the NDS was

Table 1 Numbers and percentages of people diagnosed with dementia per Primary Care Trusts (PCT per year)

Year	2006/2007	2007/2008	2008/2009	2009/2010	2010/2011	2011/2012
Median number (range) diagnosed with dementia per PCT	1088 (319–6763)	1141.5 (313–7109)	1114 (310–7047)	1186.5 (353–7527)	1286.5 (399–7765)	1419 (448–8058)
Mean dementia diagnosis percentage (SD) per PCT	36.54 (5.6)	37.10 (5.8)	35.85 (5.8)	38.27 (6.1)	40.32 (6.4)	42.29 (6.8)
Mean increase in numbers diagnosed with dementia per PCT (SD) compared to previous year	N/A	48.7 (58.6)	–37.5 (55.8)	111.6 (100.1)	99.2 (75.1)	158.5 (107.7)

launched. Prior to this, there was no clear increase in the number of diagnoses since records began in 2006/2007; therefore, the change does not seem to be just a continuation of a trend that was already occurring or established.

National spending on antidementia medication has also been increasing over time. There was a significant increase in the mean NIC every consecutive fiscal year since 2008/2009 with the decrease in 2012 probably due to the lapsing of patents of cholinesterase inhibitors in England, as prescription numbers continued to increase. We found a larger increase in items prescribed in 2010, the year after the NDS was launched and following the National Institute for Health and Care Excellence (NICE) guideline amendment in August 2009 to allow prescription of cholinesterase inhibitors for mild dementia. The costs of antidementia medications as a proportion of overall spending in PCTs also significantly increased following the launch of the NDS.

The mechanism of this change in diagnostic rates and prescriptions is unclear. The NDS involved provision of additional funding to PCTs. A government review of how this was spent found that less than half of PCTs responded to the survey, of which two-thirds were unable to say where they had allocated the money. Those who could comment on spending mostly prioritised funding memory services and early diagnosis.³⁰ It is unlikely that those who were unable to say where it was spent used it for dementia and thus it appears that most of the funding was not used for the intended purpose. Therefore, increased spending seems unlikely to be the sole mechanism of change. It is, however, clearly essential to fund services in line with growing demand and ideally this funding should be ringfenced.³¹

The other two elements of the NDS were national dementia awareness campaigns and addressing the quality of dementia care partly through the establishment of memory clinics. A memory clinic survey with an 80% response rate found that the number of people using memory services in each PCT was 1.5 times higher in 2010/2011 than in 2008/2009.³² In England, consistent with the NICE guidelines, most of the GPs do not diagnose dementia and initiate medication. An increase in diagnosis rates therefore indicates an increase in specialists' diagnoses, probably in memory clinics as they are now the assessment and diagnosis route in most services for people with suspected dementia. This accords with previous reports of an increase in numbers diagnosed with dementia with the establishment of memory clinics.^{17–33} Nationally and internationally, relabelling mental health services as 'memory clinics' may also reduce the barrier to diagnosis caused by the stigma of attending mental health services.³⁴

It may also be that GPs' and the public's opinion about obtaining a dementia diagnosis has changed with the national awareness campaigns, meaning GPs are more willing to suggest the possibility of the diagnosis and refer patients who are more willing to have further

Table 2 Results of regression analyses for dementia diagnosis and antidementia drug prescriptions

Years	Dementia diagnosis		Numbers of antidementia drug prescriptions		Cost of antidementia drugs compared with overall spending	
	Estimate* (95% CI)	p Value <0.001	Estimate† (95% CI)	p Value <0.001	Estimate‡ (95% CI)	p Value <0.001
2006	0.96 (0.53 to 0.97)		No data available		No data available	
2007	0.98 (0.97 to 0.98)		No data available		No data available	
2008	0.94 (0.93 to 0.95)		0.88 (0.84 to 0.92)		−0.95 (−1.13 to −0.68)	
2009	Reference year					
2010	1.04 (1.03 to 1.05)		1.11 (1.06 to 1.16)		0.54 (0.27 to 0.81)	
2011	1.12 (1.11 to 1.13)		1.24 (1.19 to 1.29)		2.26 (1.99 to 2.53)	

*Estimates represent incidence rate ratio of dementia diagnosis relative to year 2009 obtained from negative binomial regression, offset against population at risk.

†Estimates represent incidence rate ratio of number of antidementia drug prescriptions relative to year 2009 obtained from negative binomial regression, offset against total number of prescriptions.

‡Estimates represent the mean difference in relative cost of dementia drug obtained by multilevel linear regression compared with 2009.

Table 3 Spearman's rank correlation between numbers of people with dementia diagnoses on PCT quality outcome framework register with PCT level prescription data

Years	Correlation of dementia diagnosis against items dispensed	p Value	Correlation of dementia diagnosis against NIC	p Value
2008/2009	0.58	<0.001	0.61	<0.001
2009/2010	0.57	<0.001	0.61	<0.001
2010/2011	0.57	<0.001	0.62	<0.001
2011/2012	0.56	<0.001	0.61	<0.001

NIC, net ingredient cost; PCT, primary care trust.

assessment, but we were unable to find evidence about opinion stability or change.

Strengths and limitations

To our knowledge, this is the first study to test the effect of government policy on measureable outcomes in dementia. This is an area that deserves further study to ensure the best use of resources in managing dementia and other illnesses.

The QOF provides a financial incentive for GP practices to create and maintain a register of patients with dementia. It is a voluntary reward scheme and there has been some debate about whether it provides an accurate estimate of numbers diagnosed with dementia. We tested its validity and found the QOF data to be highly correlated with prescriptions for antidementia medication, indicating that it is a valid measure of the number of people diagnosed with dementia. There is still a

Table 4 Spearman's rank correlation between dementia diagnosis rates divided into quartiles and prescription costs

Years	Quartile (lowest to highest diagnosis rates)	Number of PCTs* in each group	Mean NIC (SD) per person on dementia register	Correlation between NIC and diagnosis rate	p Value
2009–2010	1st	37	303.4 (177.3)	0.533	0.001
	2nd	38	357.0 (131.5)	0.571	<0.001
	3rd	38	317.0 (166.5)	0.655	<0.001
	4th	37	333.8 (136.2)	0.684	<0.001
2010–2011	1st	37	329.5 (163.6)	0.497	0.002
	2nd	38	328.9 (176.5)	0.604	<0.001
	3rd	38	302.0 (164.6)	0.644	<0.001
	4th	37	358.5 (127.1)	0.764	<0.001
2011–2012	1st	37	331.4 (185.8)	0.384	0.019
	2nd	38	360.4 (167.4)	0.742	<0.001
	3rd	38	337.3 (177.3)	0.548	<0.001
	4th	37	379.3 (136.4)	0.717	<0.001

*NIC, net ingredient cost; PCT, primary care trust.

Figure 2 Rate of increase in cognitive enhancer prescriptions over time.

significant amount of variance in prescription which is unexplained by diagnosis rate. However, areas which had low diagnosis rates did not have higher prescription rates per person diagnosed with dementia, indicating that there is not a systematic omission of people with dementia from the QOF register in these areas. Although antidementia drugs are recommended in the UK across all the dementia severity ranges and there is no reason to think that the proportion of people with Alzheimer's dementia varies across areas, we do not know whether some practitioners prescribe in different ways. However, our analysis finds no systematic pattern in the PCTs with low dementia diagnosis percentages and therefore suggests that the low rates are not accounted for only by a failure to record diagnosis.

Owing to the nature of the intervention being studied, we could only establish associations and temporal links between the launch of the NDS and outcomes. It may be that there is another explanation for the changes, including a change in peoples' perceptions about dementia. This could account for the launch of the NDS and the change in diagnosis and prescription rates. Also, the NDS is a policy change with a wide remit and regional variation in its application. It is therefore difficult to say with any certainty which aspect of the NDS may account for the changes in outcomes we have seen. Finally, all our data were retrospective and not specifically collected with the aim of assessing the impact of the NDS, therefore systematic error cannot be ruled out.

Figure 3 National community net ingredient cost 2003–2012.

Although we did not have any data on the timeliness of the dementia diagnoses being made, if the increase in dementia diagnosis is due to more diagnoses being made in memory services, these diagnoses are likely to be more timely.¹⁸

Policy and research implications

More than half of people with dementia are still not diagnosed and others are diagnosed late in the illness and therefore do not have the benefits of timely diagnosis described above. If more diagnoses for dementia are made in a timely manner, this should improve individual experience of the illness and have positive implications for health and social care costs. Further effective interventions to increase the number of timely dementia diagnoses are still needed and these interventions should consider harm in terms of anxiety increase in the 'worried well' as well as benefit and cost. As more antidementia drugs come off-license in the UK, costs associated with earlier diagnosis of dementia could fall despite an increase in the number of prescriptions, which could be an important factor in assessing the costs and benefits of future interventions.

Our results suggest that government policy has a significant effect on the number of people diagnosed with dementia and prescription of antidementia drugs but this is unlikely to be due only to additional funding. In particular, more people have accessed the rebadged memory services than mental health services and it may be important to consider the public's perception of services as well as their funding and operation.

Acknowledgements The authors are very grateful to the Alzheimer's Society for their help in understanding and processing dementia diagnosis data.

Contributors SR found and imported the relevant data. NM, GL and SR wrote the first draft of the manuscript and NM is the guarantor. All authors analysed the data. All authors contributed to and agreed to the final version.

Funding The authors received no funding for this research. NM is funded by the NIHR.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

1. Luengo-Fernandez R, Leal J, Gray A. *Dementia 2010. The economic burden of dementia and associated research funding in the United Kingdom*. Cambridge: Alzheimer's Research Trust 35, 2010.
2. Ferri CP, Prince M, Brayne C, *et al*. Global prevalence of dementia: a Delphi consensus study. *Lancet* 2005;366:2112–17.
3. Matthews FE, Arthur A, Barnes LE, *et al*. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. *Lancet* 2013;382:1405–12.

4. Prince M, Bryce R, Ferri CP. *World Alzheimer Report 2011: the benefits of early diagnosis and intervention*. London: Alzheimer's Disease International, 2011.
5. Goldberg SE, Bradshaw LE, Kearney FC, *et al*. Care in specialist medical and mental health unit compared with standard care for older people with cognitive impairment admitted to general hospital: randomised controlled trial (NIHR TEAM trial). *BMJ* 2013;347:f4132.
6. Burns A. The benefits of early diagnosis of dementia. *BMJ* 2012;344:e3556.
7. Prince M, Bryce R, Ferri C. *The benefits of early diagnosis and intervention*. Alzheimer's Disease International World Alzheimer Report 2011. 2011.
8. Olafsdottir M, Foldevi M, Marcusson J. Dementia in primary care: why the low detection rate? *Scand J Prim Health Care* 2001;19:194–8.
9. Department of Health. *Living well with dementia: a national dementia strategy*. London: Department of Health, 2009.
10. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. *Lancet* 2012;380:1441–3.
11. Livingston G, Leavey G, Manela M, *et al*. Making decisions for people with dementia who lack capacity: qualitative study of family carers in UK. *BMJ* 2010;341:c4184.
12. All-Party Parliamentary Group on Dementia. *Unlocking diagnosis: All-Party Parliamentary Group report 2012*. 2012.
13. National Audit Office. *Improving services and support for people with dementia*. London: The Stationery Office, 2007.
14. National Audit Office. *Improving dementia services in England—an interim report*. 14 Jan 2010.
15. House of Commons All-Party Parliamentary Group on Dementia. *A missed opportunity? Inquiry into the funding of the National Dementia Strategy*. 2010.
16. Batsch NL, Mittelman MS. *World Alzheimer Report 2012: overcoming the stigma of dementia*. London: Alzheimer's Disease International, 2012.
17. Ramakers IH, Verhey FR. Development of memory clinics in the Netherlands: 1998 to 2009. *Aging Mental Health* 2011;15:34–9.
18. Luce A, McKeith I, Swann A, *et al*. How do memory clinics compare with traditional old age psychiatry services? *Int J Geriatr Psychiatry* 2001;16:837–45.
19. NHS prescriptions dispensed in the community. 2013. 6 Aug 2013.
20. HSCIC hospital prescribing figures. 2013. 6 Aug 2013.
21. NHS iView. 2013. 6 Aug 2013.
22. Quality Outcomes Framework (QOF), DEM2 indicator, split by PCT. 2013. 6 Aug 2013.
23. Alzheimer's society. Mapping the dementia gap 2011. 21 Feb 2012.
24. Alzheimer's society. Mapping the dementia gap 2012. 2013.
25. Prescriptions cost analysis. 2013. 6 Aug 2013.
26. Bank of England. Inflation calculator. 2013. 21 Nov 2013.
27. Cholinesterase inhibitors lapse of licenses in UK. 2013. 21 Aug 2013.
28. Gardner W, Mulvey EP, Shaw EC. Regression analysis of counts and rates: poisson, overdispersed Poisson and negative binomial models. *Psychol Bull* 1995;118:392–404.
29. Snijders TAB, Bosker RJ. *Multilevel analysis: an introduction to basic and advanced multilevel modelling*. London: Sage, 1999.
30. All-Party Parliamentary Group on Dementia. *A missed opportunity? Inquiry into the funding of the National Dementia Strategy*. 2010.
31. Hawkes N. Dementia experts are optimistic despite decline in hope for effective drugs. *BMJ* 2013;347:f4265.
32. The NHS Information Centre CaMHT. *Establishment of memory services—results of a survey of Primary Care Trusts, final figures 2011*. 2011. The Health and Social Care Information Centre.
33. Banerjee S, Willis R, Matthews D, *et al*. Improving the quality of care for mild to moderate dementia: an evaluation of the Croydon Memory Service Model. *Int J Geriatr Psychiatry* 2007;22:782–8.
34. Mukadam N, Livingston G. Reducing the stigma associated with dementia: approaches and goals. *Aging Health* 2012;8:377–86.